Dyslipidaemia in the Middle East: Current status and a call for action

Khalid Al Rasadi*, Wael Almahmeed, Khalid F. AlHabib, Marianne Abifadel, Hasan Ali Farhan, Saud AlSifri, Selim Jambart, Mohammad Zubaid, Zuhier Awan, Khalid Al-Waili, Philip Barter

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

36 Citations (Scopus)


The increase in the cardiovascular disease (CVD)-associated mortality rate in the Middle East (ME) is among the highest in the world. The aim of this article is to review the current prevalence of dyslipidaemia and known gaps in its management in the ME region, and to propose initiatives to address the burden of dyslipidaemia. Published literature on the epidemiology of dyslipidaemia in the ME region was presented and discussed at an expert meeting that provided the basis of this review article. The high prevalence of metabolic syndrome, diabetes, familial hypercholesterolaemia (FH) and consanguineous marriages, in the ME region, results in a pattern of dyslipidaemia (low high-density lipoprotein cholesterol and high triglycerides) that is different from many other regions of the world. Early prevention and control of dyslipidaemia is of paramount importance to reduce the risk of developing CVD. Education of the public and healthcare professionals and developing preventive programs, FH registries and regional guidelines on dyslipidaemia are the keys to dyslipidaemia management in the ME region.

Original languageEnglish
Pages (from-to)182-187
Number of pages6
Publication statusPublished - Sept 1 2016


  • Cardiovascular disease
  • Dyslipidaemia
  • Familial hypercholesterolaemia
  • Guidelines
  • Middle east
  • Prevalence

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Dyslipidaemia in the Middle East: Current status and a call for action'. Together they form a unique fingerprint.

Cite this